• Levels of γ-aminobutyric acid (GABA) in CSF were measured in patients with Parkinson's disease (n = 14) and sex-matched controls (n = 14). One patient underwent a spinal tap before and after treatment. The mean (± SD) CSF GABA levels were 200 ± 70 pmole/mL in controls and 121 ± 52 pmole/mL in patients with Parkinson's disease. In the untreated patients with Parkinson's disease, the CSF GABA level was 95 ± 31 pmole/mL (n = 7) and in those who were treated with levodopa and carbidopa the level was 144 ± 53 pmole/mL (n = 8). No significant difference was seen in plasma GABA levels between the controls and patients with Parkinson's disease. The decreased GABA level in CSF, which was elevated by levodopa, supports the concept that in Parkinson's disease, the GABA-dopamine interaction in the substantia nigra may be an important compensatory mechanism counteracting the dopamine neuronal loss.
Manyam BV. Low CSF γ-Aminobutyric Acid Levels in Parkinson's Disease: Effect of Levodopa and Carbidopa. Arch Neurol. 1982;39(7):391–392. doi:10.1001/archneur.1982.00510190009002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: